Zenas BioPharma

Fort Myers, United States Founded: 2020 • Age: 6 yrs
Clinical development services for autoimmune and rare diseases are provided.

About Zenas BioPharma

Zenas BioPharma is a company based in Fort Myers (United States) founded in 2020.. Zenas BioPharma has raised $318.15 million across 2 funding rounds from investors including Xencor, Norwest Venture Partners and Fairmont Hotels & Resorts. The company has 130 employees as of December 31, 2024. Zenas BioPharma offers products and services including Obexelimab. Zenas BioPharma operates in a competitive market with competitors including AllStripes, Prime Global, CTI Clinical Trial, Agility Clinical and Neurenati, among others.

  • Headquarter Fort Myers, United States
  • Employees 130 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Zenas Biopharma, Inc.
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
    $5 M
    -90
    as on Dec 31, 2024
  • Net Profit
    $-156.99 M
    -322.87
    as on Dec 31, 2024
  • EBITDA
    $-163.75 M
    -505.72
    as on Dec 31, 2024
  • Total Equity Funding
    $318.15 M (USD)

    in 2 rounds

  • Latest Funding Round
    $200.15 M (USD), Series C

    May 03, 2024

  • Investors
    Xencor

    & 18 more

  • Employee Count
    130

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Zenas BioPharma

Zenas BioPharma is a publicly listed company on the NASDAQ with ticker symbol ZBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: ZBIO . Sector: Health technology · USA

Products & Services of Zenas BioPharma

Zenas BioPharma offers a comprehensive portfolio of products and services, including Obexelimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Bifunctional antibody targeting B cell activity in autoimmune diseases.

People of Zenas BioPharma
Headcount 10-50
Employee Profiles 40
Board Members and Advisors 6
Employee Profiles
People
Joe Farmer
President & COO
People
Melissa DePaul
VP Finance and Corporate Controller
People
Chase Jayasekera
VP, Head of Legal
People
Whitney Cavanagh
VP, Portfolio & Program Management

Unlock access to complete

Board Members and Advisors
people
John Orloff
Director

Unlock access to complete

Funding Insights of Zenas BioPharma

Zenas BioPharma has successfully raised a total of $318.15M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $200.15 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series C — $200.1M
  • First Round

    (02 Nov 2022)

  • Investors Count 19
Date Amount Transaction Name Valuation Lead Investors Investors
May, 2024 Amount Series C - Zenas BioPharma Valuation SR One , New Enterprise Associates
Nov, 2022 Amount Series B - Zenas BioPharma Valuation Enavate Sciences
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Zenas BioPharma

Zenas BioPharma has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Xencor, Norwest Venture Partners and Fairmont Hotels & Resorts. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
A biotechnology venture capital firm investing in innovative science.
Founded Year Domain Location
Venture capital investments are offered to startups by NEA.
Founded Year Domain Location
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Zenas BioPharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Zenas BioPharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Zenas Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Zenas BioPharma

Zenas BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AllStripes, Prime Global, CTI Clinical Trial, Agility Clinical and Neurenati, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Provider of information to patients and communities with the medical data for rare diseases
domain founded_year HQ Location
Medical communication solutions are provided for healthcare professionals.
domain founded_year HQ Location
Provides clinical trials, consulting, and regulatory services in healthcare sectors.
domain founded_year HQ Location
CRO with a special focus on orphan drug development
domain founded_year HQ Location
Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Zenas BioPharma

When was Zenas BioPharma founded?

Zenas BioPharma was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Zenas BioPharma located?

Zenas BioPharma is headquartered in Fort Myers, United States. It is registered at Fort Myers, Florida, United States.

Is Zenas BioPharma a funded company?

Zenas BioPharma is a funded company, having raised a total of $318.15M across 2 funding rounds to date. The company's 1st funding round was a Series B of $118M, raised on Nov 02, 2022.

How many employees does Zenas BioPharma have?

As of Dec 31, 2024, the latest employee count at Zenas BioPharma is 130.

What is the annual revenue of Zenas BioPharma?

Annual revenue of Zenas BioPharma is $5M as on Dec 31, 2024.

What does Zenas BioPharma do?

Zenas BioPharma was founded in 2020 and is headquartered in Fort Myers, United States. Clinical development services are offered by the company within the biopharmaceutical sector, with a focus on autoimmune and rare diseases. Operations encompass therapeutic advancements and support for drug pipelines, targeting unmet medical needs in these areas. The companys domain, zenasbio.com, facilitates information on its activities.

Who are the top competitors of Zenas BioPharma?

Zenas BioPharma's top competitors include AllStripes, Prime Global and Agility Clinical.

What products or services does Zenas BioPharma offer?

Zenas BioPharma offers Obexelimab.

Is Zenas BioPharma publicly traded?

Yes, Zenas BioPharma is publicly traded on NASDAQ under the ticker symbol ZBIO.

Who are Zenas BioPharma's investors?

Zenas BioPharma has 19 investors. Key investors include Xencor, Norwest Venture Partners, Fairmont Hotels & Resorts, Perceptive Advisors, and Enavate Sciences.

What is Zenas BioPharma's ticker symbol?

The ticker symbol of Zenas BioPharma is ZBIO on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available